Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.

International journal of molecular sciences - 11 Aug 2020

Vilariño Noelia, Bruna Jordi, Kalofonou Foteini, Anastopoulou Garifallia G, Argyriou Andreas A

Abstract excerpt

Over the last decade, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several cancer types. ICIs work through the blockage of immune inhibitory signals, while increasing the T-cell specific immune antitumoral response. However, due to the fact that ICIs' mechanism of action is not tissue antigen-specific and not limited to the tumor microenvironment, the use of cancer immunotherapy can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Immune Tolerance

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Mimicry

Share to Neoplasms

Share to Neurotoxicity Syndromes

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 32796758
DOI: 10.3390/ijms21165774
PMCID: PMC7461114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.PMID 32796758Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read ↗

CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.Semantic proximity Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathiesSemantic proximity Read ↗

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read ↗

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read ↗

Radiation‐Induced Immunogenic Cell Death for Cancer RadioimmunotherapySemantic proximity Read ↗

CAR-T AND autoimmune diseases in nervous systemSemantic proximity Read ↗

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read ↗

Cancer-nervous system crosstalk: from biological mechanism to therapeutic opportunitiesSemantic proximity Read ↗

Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.